

Resource Summary Report

Generated by [RRID](#) on Sep 4, 2026

BCBL-1

RRID:CVCL_0165

Type: Cell Line

Proper Citation

RRID:CVCL_0165

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0165

Proper Citation: RRID:CVCL_0165

Description: Cell line BCBL-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Primary effusion lymphoma

Defining Citation: [PMID:8612236](#), [PMID:9375005](#), [PMID:9766492](#), [PMID:15613351](#), [PMID:17121789](#), [PMID:17324269](#), [PMID:19521981](#), [PMID:19608668](#), [PMID:21685375](#), [PMID:28196595](#), [PMID:31160637](#)

Comments: Karyotypic information: Has lost chromosome Y., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: BCBL-1

Synonyms: BCBL1, BCBL, Body Cavity Based Lymphoma-1

Cross References: BTO:BTO_0002727, EFO:EFO_0002048, MCCL:MCC:0000057, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, BEI_Resources:ARP-3233, BioSample:SAMN03473436, BioSamples:SAMEA365914, BioSamples:SAMEA365927, cancercellines:CVCL_0165, Cosmic:1238078, Cosmic:1515185, Cosmic:1588560, DSMZ:ACC-683, DSMZCellDive:ACC-683, GEO:GSM33134, GEO:GSM38800, GEO:GSM38801, GEO:GSM634735, GEO:GSM710421, GEO:GSM710437, GEO:GSM1265856, GEO:GSM1265857, GEO:GSM1265858, GEO:GSM1265859, GEO:GSM1265860, GEO:GSM1265868, GEO:GSM3150238, IARC_TP53:26980,

Lonza:238, PRIDE:PXD012087, Progenetix:CVCL_0165, TOKU-E:4070, Wikidata:Q54795334

ID: CVCL_0165

Record Creation Time: 20220427T215355+0000

Record Last Update: 20260904T021629+0000

Ratings and Alerts

No rating or validation information has been found for BCBL-1.

No alerts have been found for BCBL-1.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 291 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#).

Galaski J, et al. (2024) Fusobacterium nucleatum subsp. nucleatum RadD binds Siglec-7 and inhibits NK cell-mediated cancer cell killing. iScience, 27(6), 110157.

Knickmann J, et al. (2024) A simple method for rapid cloning of complete herpesvirus genomes. Cell reports methods, 4(2), 100696.

White MC, et al. (2024) Inhibition of NEK2 Promotes Chemosensitivity and Reduces KSHV-positive Primary Effusion Lymphoma Burden. Cancer research communications, 4(4), 1024.

Kotzur R, et al. (2023) Eradication of CD48-positive tumors by selectively enhanced YTS cells harnessing the lncRNA NeST. iScience, 26(8), 107284.

Tuohinto K, et al. (2023) KSHV infection of endothelial precursor cells with lymphatic characteristics as a novel model for translational Kaposi's sarcoma studies. PLoS pathogens, 19(1), e1010753.

Pan Y, et al. (2023) The Poisson distribution model fits UMI-based single-cell RNA-sequencing data. BMC bioinformatics, 24(1), 256.

Liu Y, et al. (2023) Suppressing Kaposi's Sarcoma-Associated Herpesvirus Lytic Gene Expression and Replication by RNase P Ribozyme. Molecules (Basel, Switzerland), 28(8).

Lipka E, et al. (2023) NPP-669, a Novel Broad-Spectrum Antiviral Therapeutic with Excellent Cellular Uptake, Antiviral Potency, Oral Bioavailability, Preclinical Efficacy, and a

Promising Safety Margin. *Molecular pharmaceutics*, 20(1), 370.

Li X, et al. (2023) Suppression of KSHV lytic replication and primary effusion lymphoma by selective RNF5 inhibition. *PLoS pathogens*, 19(1), e1011103.

Chen J, et al. (2023) Oncolytic strategy using new bifunctional HDACs/BRD4 inhibitors against virus-associated lymphomas. *PLoS pathogens*, 19(1), e1011089.

Tsyklauri O, et al. (2023) Regulatory T cells suppress the formation of potent KLRK1 and IL-7R expressing effector CD8 T cells by limiting IL-2. *eLife*, 12.

Chen J, et al. (2023) Role of Histamine and Related Signaling in Kaposi's Sarcoma-Associated Herpesvirus Pathogenesis and Oncogenesis. *Viruses*, 15(4).

Moore LN, et al. (2023) Bcl-xL is required to protect endothelial cells latently infected with KSHV from virus induced intrinsic apoptosis. *PLoS pathogens*, 19(5), e1011385.

Tian X, et al. (2023) Genome-Wide CRISPR-Cas9 Screen Identifies SMCHD1 as a Restriction Factor for Herpesviruses. *mBio*, 14(2), e0054923.

Sakamoto T, et al. (2023) Application of the CDK9 inhibitor FIT-039 for the treatment of KSHV-associated malignancy. *BMC cancer*, 23(1), 71.

Majerciak V, et al. (2022) Genome-wide regulation of KSHV RNA splicing by viral RNA-binding protein ORF57. *PLoS pathogens*, 18(7), e1010311.

Huang Y, et al. (2022) Targeting Glycolysis in Alloreactive T Cells to Prevent Acute Graft-Versus-Host Disease While Preserving Graft-Versus-Leukemia Effect. *Frontiers in immunology*, 13, 751296.

Benedetti R, et al. (2022) Concomitant Inhibition of IRE1 α /XBP1 Axis of UPR and PARP: A Promising Therapeutic Approach against c-Myc and Gammaherpesvirus-Driven B-Cell Lymphomas. *International journal of molecular sciences*, 23(16).

Yeh WW, et al. (2022) SUMO Modification of Histone Demethylase KDM4A in Kaposi's Sarcoma-Associated Herpesvirus-Induced Primary Effusion Lymphoma. *Journal of virology*, 96(16), e0075522.

Zhang H, et al. (2022) Mitochondrial protein, TBRG4, modulates KSHV and EBV reactivation from latency. *PLoS pathogens*, 18(11), e1010990.